General
Preferred name
LINZAGOLIX
Synonyms
KLH-2109 ()
OBE-2109 ()
LINZAGOLIX CHOLINE ()
OBE2109 ()
Klh-2109 ()
OBE2109 choline ()
Yselty ()
KLH-2109 choline ()
P&D ID
PD166333
CAS
935283-04-8
1321816-57-2
Tags
available
drug
Approved by
EMA
First approval
2022
Drug indication
Endometriosis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Linzagolix (KLH-2109) is an orally bioavailable gonadotropin-releasing hormone (GnRH) receptor antagonist . It was developed for potential to downregulate the hypothalamic pituitary-gonadal axis to inhibit the driving force of LH and FSH on estrogen release, as a mechanism to combat the symptoms associated with endometriosis , heavy menstrual bleeding or uterine fibroids .
(GtoPdb)
DESCRIPTION
Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for uterine fibroids, endometriosis, adenomyosis research[1][2][3].
PRICE
130
PRICE
749
DESCRIPTION
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Linzagolix choline is an orally available non-peptide gonadotropin-releasing hormone (GnRH) antagonist. It can be used to study pain associated with uterine fibroids and endometriosis.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
508.06
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
4
cLogP
3.45
TPSA
119.85
Fraction CSP3
0.14
Chiral centers
0.0
Largest ring
6.0
QED
0.39
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
GNRHR
GNRH Receptor
Pathway
GPCR/G protein
Source data
